论文部分内容阅读
目的：观察胸腔内注射贝伐珠单抗联合紫杉醇治疗非小细胞肺癌伴恶性胸腔积液的疗效和安全性。方法选择2012年9月至2013年9月解放军总医院第一附属医院收治的晚期非小细胞肺癌伴恶性胸腔积液患者45例，所有入组患者均接受静脉紫杉醇和顺铂化疗，将所有患者分为贝伐珠单抗联合紫杉醇组（贝伐组）21例和紫杉醇组（化疗组）24例。胸腔给药，每3周为一周期。贝伐组采用贝伐珠单抗300 mg 联合紫杉醇60 mg 进行治疗；化疗组采用紫杉醇60 mg 进行治疗。根据 RECIST 1.1评价标准和 NCI-CTC-AE 3.0分级标准评估疗效和不良反应。结果两组患者治疗后胸腔积液均呈下降趋势，治疗胸腔积液的总有效率贝伐组为81.0%，化疗组为58.3%，差异有统计学意义（P<0.05）。两组患者治疗过程中均未出现不能耐受的不良反应。结论贝伐珠单抗联合紫杉醇可以更好地控制非小细胞肺癌胸腔积液的增长。“,”Objective To explore the efficacy and safety of intrathoracic injection of paclitaxel combined with bevacizumab in the treatment of non-small cell lung cancer(NSCLC) and malignant pleural effusion(MPE). Methods From September 2012 to September 2013,all patients in the study population were treated with paclitaxel and cisplatin through intravenous injection in the First Affiliated Hospital of Chinese PLA General Hospital. A total of 45 non-small cell lung cancer patients with MPE were randomly assigned to receive intrathoracic injection of bevacizumab combined with paclitaxel(bevacizumab group, 21 cases, bevacizumab 300 mg and paclitaxel 60 mg) and paclitaxel (chemotherapy group, 24 cases, paclitaxel 60 mg) every three weeks. The efficacy and safety was evaluated according to RECIST 1.1 and NCI-CTC-AE 3.0 version criteria respectively.Results Pleural effusion was reduced in both two groups after treatment. The response rate was 81.0% in bevacizumab group and 58.3% in chemotherapy group, and there were statistically significant differences between the two groups (P<0.05). All procedures were well tolerated with no treatment-related severe side effects. Conclusion Bevacizumab combined with paclitaxel are highly effective in the treatment of MPE in NSCLC patients.